Broader utility drives market dominance: GLP1s address not only diabetes and obesity, but also cardiovascular and other metabolic comorbidities, creating opportunities to position them as multicondition solutions
Tirzepatide works as a GLP-1 agonist, plus it has a glucose-dependent insulinotropic polypeptide-1 (GIP-1) agonist
And not eating a hamburger bun but using two beef Patties in place of a bun
Effects of oral L-carnitine supplementation on lipid Profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: a randomized, double-blinded, placebo-controlled trial
Table 1) evaluating tirzepatide in people at high cardiovascular risk who are overweight or obese (without diabetes) is expected to report in 2027
BBR in combination with metformin appears to improve insulin sensitivity more [200,201,202]